Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spectral Reports 2008 Results
“In 2008, we accomplished several key objectives on our path to delivering an effective treatment for severe sepsis for the U.S. market,” said Paul Walker, president and chief
“In 2008, we accomplished several key objectives on our path to delivering an effective treatment for severe sepsis for the U.S. market,” said Paul Walker, president and chief
SciClone Pharmaceuticals, a biopharmaceutical company, has completed enrollment ahead of schedule in the company’s Phase II clinical trial for RP101 in patients with late-stage pancreatic cancer. This study
Allscripts-Misys Healthcare Solutions, a provider of clinical software, connectivity and information solutions, has signed a definitive agreement to sell its medication services business to A-S Medication Solutions. Under
Acadia Pharmaceuticals, a developer of small molecule drugs for the treatment of central nervous system disorders, has reported a net loss of $14m, or $0.38 per share, for
Vivus, a biopharmaceutical company, has reported a net loss of $6.7m, or $0.10 per diluted share, for the fourth quarter of 2008, compared to a net income of
Interleukin Genetics, a genetics-focused personalized health company, has reported a net loss of $1.47m, or $0.05 per share, for the fourth quarter of 2008, compared to a net
This 12-week, randomized, double-blind, placebo-controlled, parallel group comparative study will evaluate the safety and efficacy of Avastrem in the treatment of tardive dyskinesia (TD). The primary objective of
Lipoxen, a biopharmaceutical company, has announced positive results from its completed Phase I trial of SuliXen, its long-acting insulin candidate for type 1 and type 2 diabetes. The
In addition to chronic angina, the Genesis neurostimulation system is approved for treating chronic neuropathic pain of the trunk and limbs and pain from back surgeries that have
Ms Harrison has previously held the position of CFO for the company and takes over for Jonathan Green, CG Therapeutics’s first CEO, in an effort to move the